Circio Completes NOK300m ($29M) Financing Round to Fund Circular RNA Platform Development

Why It Matters

The funding gives a small pre‑clinical biotech the runway to validate a technology that could lower viral vector doses and extend therapeutic protein expression, a potential game‑changer for the gene‑therapy market.

Key Takeaways

• Circio raised NOK 300 million ($30 million) via warrants and private placement
• Funding extends runway to end‑20210, supporting IND filing
• circVec shows 75‑fold RNA half‑life increase vs mRNA
• Platform targets lower AAV doses and longer protein expression
• Share price jumped ~2,500% in 2025, then corrected

Pulse Analysis

Circio’s latest financing underscores how regional biotech firms can tap niche investor enthusiasm to secure sizable capital. By combining a large‑scale warrant exercise with an underwritten private placement, the Oslo‑listed company raised roughly $30 million, a notable sum for a pre‑clinical platform still in the validation stage. This infusion not only lengthens the company’s runway to 2030 but also signals confidence from over 400 investors, many of whom are existing shareholders, that the circular RNA approach merits deeper development. In a market where biotech fundraising often hinges on late‑stage data, Circio’s ability to attract capital on the back of a speculative share‑price rally illustrates the power of narrative‑driven financing.

The scientific premise of circVec rests on the stability advantages of circular RNA. Unlike linear mRNA, the closed‑loop structure resists exonuclease degradation, delivering a reported 75‑fold increase in RNA half‑life and up to 50‑fold higher protein output. For AAV‑based gene therapies, this could translate into lower vector doses, reducing manufacturing costs and immunogenicity concerns. In the emerging in‑vivo CAR‑T space, sustained antigen expression may improve efficacy while simplifying delivery logistics. By positioning circVec as a modular platform, Circio aims to address two persistent bottlenecks—dose intensity and durability—across multiple therapeutic modalities.

If Circio can convert its pre‑clinical gains into IND‑ready candidates, it could reshape competitive dynamics in the gene‑therapy arena, where giants like Spark Therapeutics and uniQure dominate. Regulators will scrutinize the safety profile of circular RNA constructs, especially regarding off‑target effects and long‑term expression. Success would likely attract partnership offers from larger pharma players seeking to augment their pipelines with next‑generation expression systems. Conversely, failure to demonstrate disease‑relevant efficacy could dampen investor enthusiasm and limit future fundraising. For now, the $30 million raise provides the runway to answer these pivotal questions, making Circio a watch‑list biotech for both scientific and financial stakeholders.

Deal Summary

Circio Holding ASA completed a NOK300 million ($29 million) financing round, raising funds through a warrant exercise and an underwritten private placement. The capital extends the company's runway to 2030 and will support the development of its circVec circular RNA expression platform. Over 400 investors participated in the transaction.